IN
INLB.US Item 9 Labs Corp
- Market cap
- USD 10.2K
- P/E
- -
- P/B
- 0.00x
- ROE
- -31.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2023.
Is INLB.US undervalued?
Graham numberThe Graham number of Item 9 Labs Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Item 9 Labs Corp fundamental analysis
No fundamental analysis for Item 9 Labs Corp yet.
Item 9 Labs Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Item 9 Labs Corp
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. It operates through Cultivation, Franchising, and Corporate segments. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona. It also operates and sells m…
Full company profileItem 9 Labs Corp financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Item 9 Labs Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 342K | 179K | 113K | 324K | 244K | 1.38M | 4.93M | 8.12M | 21.9M | 21.8M | 20.9M |
| Gross Profit | 198K | 63.8K | -4.28K | 166K | 163K | 357K | 2.38M | 3.30M | 8.61M | 7.31M | 12.2M |
| Operating Income | -1.39M | -1.11M | -1.12M | -606K | 2.21K | -691K | -4.38M | -5.33M | -5.60M | -23.1M | -7.80M |
| EBITDA | -1.50M | -15.7M | -1.72M | -2.12M | -178K | -604K | -8.93M | -4.45M | -4.35M | -22.8M | -5.79M |
| Net Income | -3.33M | -17.1M | -4.74M | -3.13M | -267K | -642K | -10.6M | -12.3M | -10.9M | -31.1M | -16.8M |
| EPS | -1.94 | -6.87 | -1.43 | -0.82 | -0.04 | -0.23 | -0.17 | -0.20 | -0.14 | -0.33 | -0.16 |
| Balance Sheet | |||||||||||
| Total Assets | 442K | 509K | 113K | 89.2K | 109K | 3.51M | 14.5M | 20.7M | 117M | 111M | 112M |
| Total Liabilities | 3.38M | 3.14M | 5.10M | 2.16M | 2.34M | 895K | 7.14M | 12.6M | 30.7M | 48.8M | 59.4M |
| Shareholders' Equity | -2.94M | -2.64M | -4.98M | -2.07M | -2.23M | 2.62M | 7.46M | 8.02M | 86.1M | 62.0M | 52.6M |
| Cash & Short-term Investments | 19.9K | 42.6K | 41.7K | 26.7K | 86.8K | 174K | 21.1K | 84.7K | 1.45M | 85.6K | 183K |
| Total Debt | 374K | 1.40M | 3.28M | 335K | 531K | 25.0K | 4.77M | 7.94M | 20.9M | 27.8M | 34.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -354K | -739K | -741K | -340K | 68.9K | -976K | -2.39M | -1.14M | -5.99M | -2.25M | -1.18M |
| Capital Expenditure | 35.5K | 16.0K | 6.71K | 0.00 | 340K | 543K | 6.46M | 406K | 2.24M | 5.46M | 94.9K |
| Free Cash Flow | -389K | -755K | -748K | -340K | 68.9K | -1.52M | -8.85M | -1.55M | -8.23M | -7.71M | -1.27M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | -24.5% | -142.5% | -153.5% | -12.7% | -50.3% | -31.8% |
| ROA | -751.5% | -3,358.3% | -4,207.8% | -3,503.4% | -245.4% | -18.3% | -73.4% | -59.5% | -9.3% | -28.1% | -15.0% |
| Net Profit Margin | -972.3% | -9,516.9% | -4,194.5% | -964.6% | -109.3% | -46.7% | -215.5% | -151.4% | -49.7% | -143.1% | -80.1% |
| Debt to Equity | - | - | - | - | - | 0.01x | 0.64x | 0.99x | 0.24x | 0.45x | 0.65x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Item 9 Labs Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | - | - | - |
| 2014 | USD 1.40M | 0.56 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Oct 18, 2018.
Who owns Item 9 Labs Corp
Ownership data of Item 9 Labs Corp is not available yet.
Item 9 Labs Corp company profile
- Company name
- Item 9 Labs Corp
- Ticker
- INLB.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 97
- Fiscal year end
- September
- Address
- 2727 North 3rd Street, Phoenix, AZ, United States, 85004
- Phone
- 833 867 6337
- Website
- item9labscorp.com
About Item 9 Labs Corp
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. It operates through Cultivation, Franchising, and Corporate segments. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona. It also operates and sells medical and adult-use cannabis dispensary franchises under the Unity Rd brand name. Item 9 Labs Corp. is headquartered in Phoenix, Arizona.
Item 9 Labs Corp management
5- Mr. Jeffrey I. RassasStrategic Advisor & Director · born 1963
- Ms. Jayne LevySenior Vice President of Communications
- Kyle JenningsVice President of Marketing
- Mr. Mark BuschSenior Vice President of Corporate Development
- Mr. Cory CarterSenior Vice President of Cultivation